Bolt Biotherapeutics Second Quarter 2023 Earnings: Misses Expectations
Bolt Biotherapeutics (NASDAQ:BOLT) Second Quarter 2023 Results
Key Financial Results
Net loss: US$18.1m (loss narrowed by 20% from 2Q 2022).
US$0.48 loss per share (improved from US$0.61 loss in 2Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Bolt Biotherapeutics Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 20%. Earnings per share (EPS) also missed analyst estimates by 1.6%.
Looking ahead, revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should learn about the 3 warning signs we've spotted with Bolt Biotherapeutics (including 1 which is a bit unpleasant).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
